

YAFO Acts as Exclusive Financial Advisor for Rhizen Pharmaceuticals in its Licensing-out Transaction with Curon Biopharma



\$150,000,000



Out-license Tenalisib to



Financial Advisor
YAFO Life Science

Oct. 12th, 2020

Transaction Overview

- Rhizen Pharmaceuticals (Rhizen Pharmaceuticals, S.A.) signs exclusive license agreement with Curon Biopharma (Curon Biopharmaceutical Limited) for the development and commercialization of Tenalisib in Greater China
- Shanghai YAFO Capital (YAFO Life Science) acted as the exclusive financial advisor on this transaction for Rhizen
- License agreement provides Rhizen with up to \$149.5 million upfront payment and milestones, plus double-digit royalties on annual net sales of Tenalisib
- Press Release Link:
- <https://www.globenewswire.com/news-release/2020/10/12/2106806/0/en/Rhizen-Pharmaceuticals-S-A-and-Curon-Biopharmaceutical-Limited-Announce-an-Exclusive-Licensing-Agreement-to-Develop-and-Commercialize-Tenalisib-a-Dual-PI3K-Delta-and-Gamma-Inhibitor.html>

About Tenalisib (RP6530)

Tenalisib (RP6530) is a highly selective, next-generation, orally active, dual PI3K delta and gamma inhibitor, that is currently in Phase 2 clinical development for hematological malignancies. Tenalisib has been granted US FDA Fast Track & Orphan-Drug Designations for treatment of relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma (R/R PTCL and R/R CTCL).

About Rhizen Pharmaceuticals

Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer and inflammatory diseases. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland.

About Curon biopharmaceutical

Curon Biopharmaceutical, founded in June 2018, is a biopharma company with facility in Shanghai focusing on developing next generation anti-cancer therapies. It completed a \$150 million USD Series A financing led by 6 Dimensions Capital, Boyu Capital, and Temasek. With its internationally experienced senior executive management team, Curon Biopharma currently holds multiple promising novel cancer immuno-therapeutic agents in its pipeline and is committed to bring next generation cancer immunotherapies to patients. Curon strive to accelerate its pipeline assets clinical development, further expand its portfolio through in-licensing and other forms of collaboration with biotech and pharmaceutical companies around the world to bring more effective treatment options to patients.

About YAFO Life Science

YAFO Life Science (YLS) is the healthcare division of YAFO Capital, which is focused on helping leading U.S. and European biopharma and MedTech companies to successfully enter the Asian market, especially in China and Japan. YLS also helps domestic pharma companies in global market research, targeting, and negotiation. Along with our local partners, YLS is dedicated to bridging the gap between global medical technologies and the Asian market. For more information regarding YAFO, go to: www.yafocapital.com

Contact

Fan Zheng
Managing Director
fzheng@yafocapital.com

Qi Li
BD Director
qli@yafocapital.com

Sean Jiang, CFA
CEO
sjiang@yafocapital.com

雅法担任 Rhizen Pharmaceuticals 独家顾问，完成与同润生物商业许可交易



交易概览

- Rhizen宣布与同润生物医药在大中华区签订处于临床阶段的磷脂酰肌醇3-激酶双重抑制剂Tenalisib的许可协议
- 上海雅法资本（雅法全球医疗）在此次交易中担任Rhizen公司的独家财务顾问
- Rhizen将获得最高1.495亿美元的授权许可首付款和里程碑付款，以及额外的二位数销售授权费。
- Press Release Link: <https://www.globenewswire.com/news-release/2020/10/12/2106806/0/en/Rhizen-Pharmaceuticals-S-A-and-Curon-Biopharmaceutical-Limited-Announce-an-Exclusive-Licensing-Agreement-to-Develop-and-Commercialize-Tenalisib-a-Dual-PI3K-Delta-and-Gamma-Inhibitor.html>

交易资产介绍

Tenalisib (RP6530) 是一款全球领先的，具有高度选择性的口服PI3K双重抑制剂。其在复发性及/或难治性外周T细胞淋巴瘤和复发性及/或难治性表皮T细胞淋巴瘤中均取得出色的临床有效性及安全性数据，并于2018年4月获得了美国FDA授予的快速通道资格，于2017年12月获得美国FDA授予的孤儿药资格。

关于 Rhizen

总部位于瑞士La-Chaux-de-Fonds的Rhizen制药是一家创新的临床阶段生物制药公司，致力于开发治疗癌症、免疫和代谢紊乱的新型治疗药物。2008年成立以来，已经开发了多种针对多种癌症和免疫相关细胞通路的专利药物候选药。

关于同润生物医药

同润生物医药是一家立足于中国、放眼于世界的创新型生物药研发企业，于2018年6月成立，并获得由通和毓承资本、淡马锡及博裕资本共同领投的1.5亿美元A轮融资。公司现已布局并构建丰富且极具竞争力的产品管线，拥有数个具有创新性的新一代肿瘤免疫治疗分子。

关于雅法全球医疗

雅法全球医疗 (YAFO Life Science) 是雅法资本旗下的医疗大健康部门。专注于帮助具有“中国角度”的海外医药企业在中国的授权、战略合作及融资；以及为中国创新药企业提供海外市场授权机会、海外市场咨询、寻找和引进海外标的服务。我们致力于成为全球医疗技术对接中国市场与资本的桥梁。目前海外有超过三十位资深合伙人，深度覆盖美国、欧洲、日本、韩国等全球医疗创新区域。

联系我们

郑帆
Managing Director
fzheng@yafocapital.com

黎琦
BD Director
qli@yafocapital.com

蒋晓阳, CFA
CEO
sjiang@yafocapital.com

YAFO Acts as Exclusive Financial Advisor for Flexion Therapeutics in its Licensing-out Transaction with Tainuo



Transaction Overview

- Flexion signs exclusive license agreement with Hong Kong Tainuo Pharma Ltd. (HK Tainuo) and Jiangsu Tainuo (a subsidiary of China Shijiazhuang Pharmaceutical Company, CSPC, one of the top 3 pharma company in China with market cap of 12 billion USD) for the development and commercialization of ZILRETTA in Greater China
- Shanghai YAFO Capital (YAFO Life Science) acted as the exclusive financial advisor on this transaction for Flexion
- License agreement provides Flexion with \$10 million upfront payment, up to \$32.5 million in milestones, and additional fees for the supply of ZILRETTA
- Flexion Press Release Link: <https://www.globenewswire.com/news-release/2020/04/01/2009879/0/en/Flexion-Therapeutics-Announces-ZILRETTA-License-Agreement-and-Provides-Business-Update-Amid-Coronavirus-Pandemic.html>

\$42,500,000



Out-license ZILRETTA® to

Jiangsu Tainuo
Subsidiary of CSPC 石药集团

Financial Advisor
YAFO Life Science

April 01, 2020

About ZILRETTA

On October 6, 2017, ZILRETTA was approved by the U.S. FDA as the first and only extended-release intra-articular therapy for patients confronting osteoarthritis-related knee pain. ZILRETTA employs proprietary microsphere technology combining triamcinolone acetonide — a commonly administered, short-acting corticosteroid — with a poly lactic-co-glycolic acid (PLGA) matrix to provide extended pain relief. The pivotal Phase 3 trial on which the approval of ZILRETTA was based showed that ZILRETTA significantly reduced knee pain for 12 weeks, with some people experiencing pain relief through Week 16.

About Flexion Therapeutics (Nasdaq: FLXN)

Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Visit flexiontherapeutics.com.

About HK Tainuo

Hong Kong Tainuo Pharma Limited (HK Tainuo) is a pharmaceutical company located in Hong Kong, China, focusing on commercializing innovative and cutting-edge therapies and medications to address the unmet medical needs in the Asia Pacific region. With its strong sales and marketing expertise and capabilities and its nationwide commercial presence and distribution network, HK Tainuo is specialized in marketing and commercializing the OA, CV and CNS brands & generics across China, among others.

About YAFO Life Science

YAFO Life Science (YLS) is the healthcare division of YAFO Capital, which is focused on helping leading U.S. and European biopharma and MedTech companies to successfully enter the Asian market, especially in China and Japan. YLS also helps domestic pharma companies in global market research, targeting, and negotiation. Along with our local partners, YLS is dedicated to bridging the gap between global medical technologies and the Asian market. For more information regarding YAFO, go to: www.yafocapital.com

Contact

Fan Zheng
Managing Director
fzheng@yafocapital.com

Qi Li
BD Director
qli@yafocapital.com

Sean Jiang, CFA
CEO
sjiang@yafocapital.com

雅法担任 Flexion Therapeutics 独家顾问，完成与泰诺医药商业许可交易



交易概览

- Flexion宣布与香港泰诺制药有限公司（“香港泰诺”）和江苏泰诺医药有限公司（以下简称“江苏泰诺”）在大中华区签订ZILRETTA的许可协议
- 上海雅法资本（雅法全球医疗）在此次交易中担任Flexion公司的独家财务顾问
- Flexion将获得1000万美元的首付款，总额高达3250万美元的开发、注册和商业销售里程碑付款。
- Flexion Press Release Link: <https://www.globenewswire.com/news-release/2020/04/01/2009879/0/en/Flexion-Therapeutics-Announces-ZILRETTA-License-Agreement-and-Provides-Business-Update-Amid-Coronavirus-Pandemic.html>

\$42,500,000

flexion
Transformative Medicine...
Where It Matters

Out-license ZILRETTA® to

Jiangsu Tainuo
Subsidiary of 石药集团
CSPC

Financial Advisor
YAFO Life Science

April 01, 2020

交易资产介绍

ZILRETTA是一种用于膝关节炎的止痛药物。该产品在2017年底获得FDA批准，是目前首个也是唯一一款FDA批准的用于缓解膝关节炎疼痛的关节腔内注射的缓释药物。ZILRETTA的核心技术是基于聚乳酸-羟基乙酸共聚物（PLGA）微球的缓释给药技术，为膝骨关节炎患者提供长效的镇痛效果。

关于 Flexion

Flexion Therapeutics, Inc. (纳斯达克股票代码: FLXN) 是一家生物制药公司，致力于开发和商业化用于治疗骨骼肌肉疾病的新颖局部疗法。该公司的主要产品ZILRETTA是一款治疗膝关节炎的长效缓释型糖皮质激素注射剂。公司的核心价值观是专注，创新，坚韧，透明和有趣。

关于香港泰诺

香港泰诺医药开发有限公司致力于创新和尖端的疗法药物的商业化，以满足亚太地区尚未满足的医疗需求。凭借强大的销售和营销专业知识与能力以及遍布全国的业务网络和分销网络，香港泰诺在中国各地区对骨关节炎、心血管、CNS等领域的原研及仿制药品进行专业的营销和商业化活动。

关于雅法全球医疗

雅法全球医疗 (YAFO Life Science) 是雅法资本旗下的医疗大健康部门。专注于帮助具有“中国角度”的海外医药企业在中国的授权、战略合作及融资；以及为中国创新药企业提供海外市场授权机会、海外市场咨询、寻找和引进海外标的服务。我们致力于成为全球医疗技术对接中国市场与资本的桥梁。目前海外有超过三十位资深合伙人，深度覆盖美国、欧洲、日本、韩国等全球医疗创新区域。

联系我们

郑帆
Managing Director
fzheng@yafocapital.com

黎琦
BD Director
qli@yafocapital.com

蒋晓阳, CFA
CEO
sjiang@yafocapital.com

YAFO Acts as Exclusive Financial Advisor for Tarveda Therapeutics in its Licensing-out Transaction with SciClone



\$75,000,000

TARVEDA
THERAPEUTICS

Out-license PEN-866 to

SCI CLONE
PHARMACEUTICALS

Financial Advisor

YAFO Life Science

March 19, 2020

Transaction Overview

- Tarveda entered into an exclusive licensing agreement to co-develop and commercialize PEN-866 upon approval in the Greater China Region with SciClone
- Shanghai YAFO Capital (YAFO Life Science) acted as the exclusive financial advisor on this transaction for Tarveda
- Per the agreement, SciClone will pay Tarveda an upfront payment of U.S. \$4 million with the right to make a future equity investment in Tarveda of up to U.S. \$5 million. Tarveda will be eligible to receive up to \$75 million in aggregate development, approval and commercial sales milestone payments. Tarveda is also eligible to receive royalties based on sales in the Greater China territory.
- Tarveda Press Release Link:

<https://www.businesswire.com/news/home/20200319005765/en/>

About PEN-866

PEN-866 is a miniature drug conjugate that preferentially binds to the activated form of HSP90 in solid tumors and is linked to the topoisomerase 1 inhibitor (SN-38), a potent anti-cancer payload. PEN-866 is designed to accumulate and be retained in tumors. PEN-866 has recently completed the Phase 1, all-comers, dose escalation and safety portion of its Phase 1/2a clinical trial. PEN-866 is the first miniature drug conjugate from Tarveda's HSP90 binding drug conjugate platform.

About Tarveda

Tarveda Therapeutics is a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies. Tarveda's second clinical program, PEN-221, is a Pentarin miniature drug conjugate currently in clinical evaluation for the treatment of patients with solid tumors expressing somatostatin receptor 2, or SSTR2, on the cell surface as is seen in neuroendocrine tumors and small cell lung cancer. PEN-221 is currently progressing through its Phase 2a trial. For more information regarding Tarveda, go to: <https://www.tarvedatx.com/>.

About SciClone

SciClone Pharmaceuticals is a private-owned specialty pharmaceutical company with a substantial commercial business in Greater China and a product portfolio focusing oncology and infectious diseases. SciClone's proprietary lead product, ZADAXIN® (Thymalfasin), is approved in over 30 countries and may be used for the treatment of certain cancers, hepatitis, and as a vaccine adjuvant, according to the local regulatory approvals. In addition, SciClone currently market a number of oncology products as commercial partner for Baxter, Pfizer and Boston Scientific in China. For more information regarding to SciClone, go to: <http://www.sciclone.com/>.

About YAFO Life Science

YAFO Life Science (YLS) is the healthcare division of YAFO Capital, which is focused on helping leading U.S. and European biopharma and MedTech companies to successfully enter the Asian market, especially in China and Japan. YLS also helps domestic pharma companies in global market research, targeting, and negotiation. Along with our local partners, YLS is dedicated to bridging the gap between global medical technologies and the Asian market. For more information regarding YAFO, go to: www.yafocapital.com

Contact

Fan Zheng
Managing Director
fzheng@yafocapital.com

Qi Li
BD Director
qli@yafocapital.com

Sean Jiang, CFA
CEO
sjiang@yafocapital.com

雅法担任 Tarveda Therapeutics 独家顾问，完成与赛生生物商业许可交易



\$75,000,000

TARVEDA
THERAPEUTICS

Out-license PEN-866 to

SCI CLONE
PHARMACEUTICALS

Financial Advisor

YAFO Life Science

March 19, 2020

交易概览

- Tarveda Therapeutics 宣布与 SciClone Pharmaceuticals International 在大中华区签订PEN-866的授权交易合同
- 上海雅法资本（雅法全球医疗）在此次交易中担任Tarveda公司的独家财务顾问
- SciClone将向Tarveda支付400万美元预付款，并有权对Tarveda进行不超过500万美元的未来股权投资。Tarveda将有资格获得总额高达7500万美元的开发，批准和商业销售里程碑付款。
- Press Release Link:

<https://www.businesswire.com/news/home/20200319005765/en/>

交易资产介绍

PEN-866是一种微型药物偶联物。PEN-866被设计为在肿瘤中积累并保留在肿瘤中。随着SN-38有效载荷随着时间的流逝在肿瘤中裂解，SN-38在肿瘤中的持续释放导致DNA损伤延长和肿瘤消退。PEN-866最近已完成其1/2a期临床试验的1期，所有患者的剂量递增和安全性试验。

关于 Tarveda

Tarveda Therapeutics是一家临床阶段的生物制药公司，专注于研发肿瘤领域的创新治疗药物。公司的核心产品是两款临床阶段肿瘤治疗适应症的小分子药物偶联物（SMDC）研发平台。公司的股东包括世界知名医疗基金Versant Ventures, NEA, Novo A/S, NanoDimension等，融资总额超过1亿美金。

关于赛生医药

赛生医药是一家私有专业制药公司，专注于研发和商业化肿瘤学和感染性疾病领域的高质量药品，在大中华区拥有大量业务。赛生医药致力于通过提供具有国际水平的医疗产品和服务来提高患者的健康。公司具有强大的产品管线，旨在解决严重和特殊疾病领域，特别是在肿瘤学领域未被满足的需求。

关于雅法全球医疗

雅法全球医疗（YAFO Life Science）是雅法资本旗下的医疗大健康部门。专注于帮助具有“中国角度”的海外医药企业在中国的授权、战略合作及融资；以及为中国创新药企业提供海外市场授权机会、海外市场咨询、寻找和引进海外标的服务。我们致力于成为全球医疗技术对接中国市场与资本的桥梁。目前海外有超过三十位资深合伙人，深度覆盖美国、欧洲、日本、韩国等全球医疗创新区域。

联系我们

郑帆
Managing Director
fzheng@yafocapital.com

黎琦
BD Director
qli@yafocapital.com

蒋晓阳, CFA
CEO
sjiang@yafocapital.com